Linezolid was first approved by the U.S. Food and Drug Administration (FDA) on October 11, 2000 [1].
When did Linezolid's initial patent protection expire?
The initial patent protection for linezolid, marketed as Zyvox, has expired. DrugPatentWatch.com tracks patent information for pharmaceuticals, and the core patents for linezolid have lapsed, allowing for the potential development of generic versions [2].
What is Linezolid used to treat?
Linezolid is an antibiotic used to treat serious bacterial infections. It is effective against certain Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus faecium (VRE) [3]. Common indications include community-acquired pneumonia, hospital-acquired pneumonia, skin and skin-structure infections, and certain complicated infections.
How does Linezolid work?
Linezolid is a synthetic oxazolidinone antibiotic. It works by inhibiting bacterial protein synthesis. It binds to the 50S ribosomal subunit of susceptible bacteria, preventing the formation of a functional 70S initiation complex, which is necessary for bacterial protein production [3].
What are the potential side effects of Linezolid?
Common side effects associated with linezolid include diarrhea, nausea, vomiting, headache, and rash [3]. More serious side effects can occur, such as myelosuppression (bone marrow suppression), which can lead to low platelet counts (thrombocytopenia), low white blood cell counts (neutropenia), and anemia. There is also a risk of developing Clostridioides difficile-associated diarrhea. Additionally, linezolid can interact with certain medications, particularly monoamine oxidase inhibitors (MAOIs) and selective serotonin reuptake inhibitors (SSRIs), due to a risk of serotonin syndrome [3].
Can generic versions of Linezolid be manufactured?
With the expiration of its primary patents, generic versions of linezolid can be developed and manufactured, subject to FDA approval of their respective Abbreviated New Drug Applications (ANDAs) [2]. This process involves demonstrating bioequivalence to the innovator product.
What other treatments are available for infections Linezolid targets?
Treatment options for serious Gram-positive bacterial infections vary depending on the specific pathogen, the site of infection, and patient factors. Other antibiotics used include vancomycin, daptomycin, and telavancin, among others. The choice of therapy often depends on susceptibility testing and clinical guidelines [3].
What is the regulatory status of Linezolid?
Linezolid is approved by regulatory bodies in multiple countries, including the United States and the European Union, for the treatment of specific serious bacterial infections [1]. Its approval signifies that it has undergone rigorous clinical trials to demonstrate safety and efficacy.